AADI Bioscience AADI Bioscience AADI Bioscience
Navigation
  • Company
    • The Company
    • Leadership
    • Board of Directors
  • Our Science
    • mTOR Pathway
    • TSC1 &TSC2
    • nab Technology Platform
    • Publications and Abstracts
  • Our Medicine
    • Our Medicine
    • Advanced Malignant PEComa
  • Pipeline
  • Patients
    • Overview
    • Patient Advocacy
    • Clinical Trials
  • Investors & News
    • IR Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • Press Releases
    • Event Calendar
    • Presentations
      • Corporate Presentations
      • Scientific Presentations
    • Financial
      • SEC Filings
      • Financial Reports
      • Quarterly Results
      • Forms
    • Governance
      • Governance Highlights
      • Committee Composition
    • IR Resources
      • Investor FAQ
      • Information Request
      • Email Alerts
      • IR Contacts
  • Contact Us
    • General Contact
    • For Healthcare Professionals
    • Careers

Battle Lines

Home Battle Lines
Jul
29

Battle Lines

admin   No comments yet

Related Portfolios

Audio Player
shadow
Fortune Elephant Dream
shadow
Left Sidebar Portfolio Post
shadow
TULKOU
shadow
The Colorful Red-Eyed Frog
shadow
Gallery
Thumbnail Gallery
shadow
HTML5 Video Post
shadow
Synchronizing Application
shadow
View Gallery
Gallery in Lightbox
shadow
Messaging Application
shadow
Fullwidth Portfolio Post
shadow
Social Media
shadow

Recent Articles

  • Baiteng Zhao, PhD
  • A Phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
  • Antitumor activity of nab-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts
  • Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines
  • Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors
  • Home
  • Leadership
  • Pipeline
  • Patients
  • Contact
  • Careers
  • Terms & Conditions
  • Privacy